Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $26

Benzinga · 05/07 15:57
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and lowers the price target from $34 to $26.